• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX AFX; INFRARENAL AORTIC EXTENSION

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX AFX; INFRARENAL AORTIC EXTENSION Back to Search Results
Model Number A28-28/C55
Device Problems Loss of or Failure to Bond (1068); Leak/Splash (1354); Dent in Material (2526); Unintended Movement (3026)
Patient Problem Failure of Implant (1924)
Event Date 12/13/2018
Event Type  Injury  
Manufacturer Narrative
The devices involved in this event will not be returned for evaluation and remain implanted in the patient.If additional information is obtained at a later time that is pertinent to this event, a follow-up report will then be submitted.
 
Event Description
The patient was initially treated with the afx2 abdominal aortic aneurysm stent.Approximately two (2) years post initial procedure, it was discovered that the graft has shifted laterally and the cuff has become "bird beaked" (material invagination) at its distal end with a possible type iiia endoleak, and a type ii endoleak present.The physician plans to reline and will continue to monitor the patient.There have been no additional patient sequelae reported.This report is only for the cuff (infrarenal aortic extension).A separate report will be filed for the main body (bifurcated stent graft).
 
Manufacturer Narrative
At the completion of the clinical evaluation and based on the information received, there was substantial evidence to support the following observations: no type iiiia andoleak, but presence of a type ii endoleak from lumbar artery.In addition, clinical assessment confirmed that the graft shifted laterally based on the discharge summary.No procedure-related harms post the secondary endovascular procedure were identified.The device, user, procedure, or anatomy relatedness of this complaint could not be determined.The procedure-related harms identified were the type ii endoleak from the lumbar artery.The final patient status was stable and discharged three days post the secondary endovascular procedure.The manufacturing lot review confirmed all devices met specifications prior to release.These types of events will be monitored and trended as part of the quality system.
 
Event Description
Additional information received confirming that the physician elected to treat the patient by relining with a bifurcated afx2 and an infrarenal afx devices on (b)(6) 2019.In addition, clinical assessment refuted the reported type iiia endoleak.This report is only for the proximal extension (infrarenal aortic extension).Reference mfr.Report # 2031527-2019-00038 for report to the bifurcated stent graft.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AFX
Type of Device
INFRARENAL AORTIC EXTENSION
Manufacturer (Section D)
ENDOLOGIX
2 musick
irvine CA 92618
MDR Report Key8262251
MDR Text Key133687123
Report Number2031527-2019-00039
Device Sequence Number1
Product Code MIH
UDI-Device Identifier00818009010278
UDI-Public(01)00818009010278(17)18083
Combination Product (y/n)N
PMA/PMN Number
P040002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Type of Report Initial,Followup
Report Date 12/19/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/18/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date08/03/2018
Device Model NumberA28-28/C55
Device Lot Number1376193-007
Was Device Available for Evaluation? No
Date Manufacturer Received12/19/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
AFX2-AFX2 BIFURCATED STENT GRAFT:1575320-003
Patient Outcome(s) Other; Required Intervention;
Patient Age75 YR
-
-